Dyne Therapeutics, Inc. (DYN)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Dyne Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Dyne Therapeutics, Inc. (DYN) has returned -7.31% so far this year and 73.33% over the past 12 months.

Based on dividend-adjusted daily data since Sep 17, 2020, DYN's average daily return is +0.10%, while the average monthly return is +2.01%. At this rate, your investment would double in approximately 2.9 years.

Historically, 43% of months were positive and 57% were negative. The best month was Oct 2025 with a return of +78.5%, while the worst month was May 2022 at -39.7%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 7 months.

On a daily basis, DYN closed higher 47% of trading days. The best single day was Oct 27, 2025 with a return of +41.2%, while the worst single day was Jan 10, 2025 at -31.2%.

Dyne Therapeutics, Inc. has an annualized alpha of 5.71%, beta of 1.53, and R² of 0.11 versus S&P 500 Index. Calculated based on daily prices since September 18, 2020.

• This stock participated in 155.12% of S&P 500 Index downside but only 85.54% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.11 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

DYN ranks 68 for risk / return — better than 68% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The table below present risk-adjusted performance metrics for Dyne Therapeutics, Inc. (DYN) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Dyne Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Dyne Therapeutics, Inc. was 85.52%, occurring on Apr 8, 2025. The portfolio has not yet recovered.

The current Dyne Therapeutics, Inc. drawdown is 61.46%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Dyne Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Dyne Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.